Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
- Trial name
- NCT02327845
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- University of Miami
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Therapy in Amyotrophic Lateral Sclerosis (TAME)
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their…
- Trial name
- TAME (NCT02118727)
- Testing
- Memantine
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Kansas Medical Center
Motor Neuron Disease
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
The COMMEND Study will assess the safety and effectiveness of FLX-787 in men and women with Motor Neuron Disease [including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy…
- Trial name
- NCT03196375
- Testing
- FLX-787-ODT (orally disintegrating tablet)
- Where
- 35 sites in United States
- Volunteers
- 54 people
- Sponsor
- Flex Pharma, Inc.
Amyotrophic Lateral Sclerosis
ASSESS ALL ALS Study
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control…
- Trial name
- NCT06578195
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Registry
This study takes amyotrophic lateral sclerosis (ALS) patients as the main research object. Through collecting genetics, imaging and clinical symptoms for Exploratory research, we will construct the gene spectrum of ALS in China…
- Trial name
- NCT05892822
- Testing
- Amyotrophic Lateral Sclerosis
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- yilong Wang
Amyotrophic Lateral Sclerosis
Longitudinal Study of Outcomes Measures in ALS Trials
A new strength measurement device called Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure static limb strength in patients with ALS.
- Trial name
- NCT01911130
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no effective treatment.
- Trial name
- NCT05095571
- Testing
- EH301 (Nicotinamide Riboside/Pterostilbene)
- Where
- 17 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Haukeland University Hospital
ALS, Amyotrophic Lateral Sclerosis
A Study to Explore the Role of Gut Flora in ALS
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding ALS
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- NCT04150809
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Amyotrophic Lateral Sclerosis
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Patients with rapidly progressive ALS will be assigned to IC14 intravenously on Day 1-4. This 4-day course will be repeated on Days 8-11.
- Trial name
- NCT03474263
- Testing
- Biologic: IC14 (monoclonal antibody against human CD14)
- Where
- Australia
- Sponsor
- Implicit Bioscience
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis
Genetics of Familial and Sporadic ALS
We are collecting blood samples, clinical and family information from ALS (amyotrophic lateral sclerosis) patients and their families to identify causes of ALS and ALS/dementia.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease
- Trial name
- ALS (NCT00821132)
- Testing
- Genetic study of ALS families
- Where
- United States
- Volunteers
- 13,521 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Amyotrophic Lateral Sclerosis
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.
- Trial name
- NCT01281631
- Testing
- NP001
- Where
- 17 sites in United States
- Volunteers
- 136 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials
Trials evaluating new therapies for stopping or slowing the progression of ALS depend critically upon the use of outcome measures to assess whether a potential treatment is effective.
- Trial name
- NCT00620698
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Beth Israel Deaconess Medical Center
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.
- Trial name
- REFALS (NCT03505021)
- Testing
- Levosimendan
- Where
- 104 sites in United States, Australia and 12 more
- Volunteers
- 496 people
- Sponsor
- Orion Corporation, Orion Pharma
ALS (Amyotrophic Lateral Sclerosis)
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
- Trial name
- NCT03241784
- Testing
- Autologous T-regulatory lymphocytes, Interleukin-2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Methodist Hospital Research Institute
Inclusion Body Myositis (IBM), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition
The aim of the study is to characterize 30 patients exhibiting muscular atrophy and weakness who require a muscle biopsy for diagnosis (suspected inclusion body myopathy vs atypical motor neuron disease), through an innovative…
- Trial name
- TDP-signatures (NCT07796776)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
ALS
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03472950
- Testing
- Ranolazine 500 MG, Ranolazine 1000 MG
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis (ALS)
A Study to Evaluate the Performance of a Diagnostic Test in ALS
Prospective multicenter study of subjects who were recently diagnosed with amyotrophic lateral sclerosis (ALS) or another neurodegenerative disease (including spinal cord diseases, muscle diseases and neurological diseases such…
- Trial name
- NCT02759913
- Testing
- Lumbar puncture
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Iron Horse Diagnostics, Inc.
Amyotrophic Lateral Sclerosis
Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurological disease. Nonspecific symptoms lead to a delay in the diagnosis, only confirmed by the electrophysiologic study. Objectives. 1.
- Trial name
- ALS (NCT02507713)
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Católica San Antonio de Murcia
Amyotrophic Lateral Sclerosis
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
- Trial name
- NCT06392126
- Testing
- nL-CHCHD-001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Amyotrophic Lateral Sclerosis (ALS), Emotional Distress
Resiliency Intervention for Patients With ALS and Their Care-Partners
The purpose of this study is to pilot a resiliency and coping intervention for persons recently diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their primary informal caregivers.
- Trial name
- RT-ALS (NCT06968468)
- Testing
- Resilient Together ALS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital